Figure 1 from Upregulation of Somatostatin Receptor Type 2 Improves 177Lu-DOTATATE Therapy in Receptor-Deficient Pancreatic Neuroendocrine Tumor Model
Year: 2023
Type: other
Abstract: SSTR2 promoter methylation levels in GEP-NET patients (A and B) and three NET cell lines (C). A, An NIH cohort of 96 patients with GEP-NETs was analyzed on the basis of tumor grade and methylation level. Those patients with higher-grade tumors showed increased methylation levels at the CpG methylation sites of the SSTR2 promoter. Significant changes were observed in the methylation levels between grades 1 and 2 (P = 0.034), grades 2 and 3 (P = 0.044), and grades 1 and 3 (P = 0.000014). B, The GSE117852 dataset of 32 patients with PNETs was analyzed for gene expression and mean SSTR2 promoter methylation levels, using the Spearman method to calculate the R and P value. C, Methylation levels and SSTR2 expression were measured before and after treatment with VPA and azacytidine (TRTM) in three NET cell lines (QGP-1, BON-1, GOT-1). The controls are untreated for comparison (CTRL). The x-axis represents the degree of methylation (0–1), adjusted graphically for optimal visual display. The most significant changes were observed at CpG island cg14232289 (P < 0.0001).
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4386485150